About Avrio MedTech
Driving precision neuroscience through intracranial EEG innovation for epilepsy
At Avrio MedTech, we develop advanced software solutions to transform how intracranial EEG (iEEG) data is analyzed and understood, accelerating progress in epilepsy research, neuroscience, and therapeutic innovation.
Our team
When medical research meets engineering
Our team combines deep expertise in neuroscience, engineering, data science, and healthcare management. We work closely with clinicians, engineers and researchers at Toulouse University Hospital, who contribute at multiple stages of design, validation and deployment.
Karine Seymour
MEng, eMBA
Co-founder, CEO
As an experienced entrepreneur, Karine joined forces with researchers to establish Avrio MedTech.
Emmanuel Barbeau
PhD
Co-founder, Clinical Lead
CNRS Director of Research specializing in declarative memory and epilepsy. Emmanuel co-founded Avrio MedTech to translate research into practical applications.
Christophe Hurter
PhD
Co-founder, Data science Lead
As an expert in data visualization and explainable artificial intelligence (XAI) at ENAC, Christophe contributes his AI and new technology proficiency to the company’s technological developments.
-
Clarissa Baratin
PhD Research Officer in Electrophysiology
-
Loïc Ferreira
MEng Data Scientist
-
Joël Lootvoet
MEng Lead SW Developer
-
Adrien Escoubeyrou
MEng UI Designer & Developer
-
Halissath Akadiri
MEng Product Specialist
-
Filippo Maschio
MEng Sales & Regulatory Affairs
-
Laure Saint-Aubert
PhD
Marketing and Customer Success Director
Avrio MedTech originates from more than a decade of academic research conducted at:
CerCo (Brain and Cognition Research Center) - CNRS / Toulouse University
CHU Toulouse (Toulouse University Hospital)
ENAC (French Civil Aviation University)
This work focused on studying high-frequency oscillations (HFOs) using innovative micro-scale electrodes capable of recording brain activity at the neuronal level.
The first version of what would become Halyzia® was developed during a PhD co-supervised by:
Emmanuel Barbeau, CNRS Research Director, epilepsy specialist
Christophe Hurter, Professor at ENAC, expert in data visualization and AI
With the support of Toulouse Tech Transfer, the technology was protected, matured, and transferred into a startup.
In early 2023, Karine Seymour, an experienced health-tech entrepreneur and founder of Medexprim, joined the academic team. Together, they founded Avrio MedTech in August 2023 - named after the Greek word for “tomorrow” - with the ambition of extending this technology to improve care for patients with drug-resistant epilepsy.
Our story
Our vision
Avrio MedTech pursues five core objectives:
1. Increase reliability and reduce interpretation time of intracranial EEG (SEEG) recordings
2. Facilitate adoption of SEEG by centers new to invasive monitoring
3. Improve outcomes of epilepsy surgery for drug-resistant patients
4. Enable precise parameterization of emerging therapies such as thermo-coagulation and neurostimulation
5. Accelerate development and personalization of next-generation epilepsy treatments
Our values
Social impact & responsibility
Avrio MedTech is a registered social economy company, structuring its operations around solidarity, social utility, and patient impact. Our primary objective is to improve the quality of life of people living with drug-resistant epilepsy.
Social impact & responsibility
We believe meaningful innovation emerges from close collaboration between researchers, clinicians, engineers and industry guided by scientific excellence and transparency.
Social impact & responsibility
We believe diversity in all its forms is a strength. Our multidisciplinary team brings together complementary expertise and perspectives to solve complex healthcare challenges.
The challenge we address
30% of patients with epilepsy do not respond properly to drugs - about 20M people in the world. For some, surgery remains the only validated curative option, yet only 400 epilepsy surgeries are performed annually in France, while 5,000 to 10,000 patients could benefit each year.
When surgery remains the only validated curative option, localizing the epileptogenic zone is a major challenge, and requires invasive pre-surgery monitoring using intracranial EEG (iEEG) through deep electrodes. After weeks of brain signal recording, only 65% of patients will proceed to surgery, often due to inconclusive analyses derived from under-exploited large datasets.
Yet outcomes are strong: most operated patients experience fewer seizures, and 55% remain seizure-free after five years.
At Avrio MedTech, we convert the information buried in iEEG data into actionable insight. We considerably reduce the hassle of reading iEEG, provide immediate insights even in the absence of a seizure, allowing for shorter patient stays, more comfort and access to innovative therapies.
The scientific breakthrough
Multiple studies have demonstrated the relevance of High Frequency Oscillations (HFOs), brief, millisecond-scale events occurring outside seizure periods, as reliable biomarkers of the epileptogenic zone. These events are invisible to the naked eye and require automated detection
BY ENABLING OBJECTIVE, QUANTITATIVE DETECTION OF THESE BIOMARKERS, ADVANCED INTRACRANIAL EEG ANALYSIS CAN:
→ Improve identification of the epileptogenic zone
→ Increase surgical eligibility
→ Reduce diagnostic delays
→ Accelerate validation of emerging therapies
→ Enable immediate response assessment during therapeutic development
Awards
2025
Winner of Women TechEU
2024
Finalist at
the Shark Tank Competition
DESIRE Eurocluster
“Product and service of the Future”
Bourse French Tech Emergence
2023
Our location
The whole team is located in the B612 innovation center in Toulouse. This flagship innovation hub is located in the heart of the Toulouse Aerospace district. Named after the famed asteroid from Antoine de Saint-Exupéry’s novel The Little Prince, B612 reflects the spirit of creativity, curiosity, and exploration that drives the whole innovating industry also at the heart of Avrio MedTech’s values.
Avrio MedTech
B612 - Centre d'innovation de Toulouse Aerospace
ANITI - 6ème étage
3 Rue Tarfaya, 31400 Toulouse
